Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections
1 December 2021
| Su Young
|
EYE - Vitreo-Retinal
|
IVI, In-house compounded, bevacizumab, compounding pharmacy, endophthalmitis
This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...
Short-term effects of intravitreal bevacizumab on the cornea
1 December 2014
| Khadijah Basheer
|
EYE - Cornea, EYE - General
|
anterior chamber depth, bevacizumab, central corneal thickness, intraocular pressure, iridocorneal angle, simulated keratometry
Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may...
